Close Menu

hepatitis

With the patented Dual Path Platform as its foundation, Chembio is expanding its commercial and manufacturing capabilities, its CEO said.

Several companies will receive grants to develop hepatitis C molecular point-of-care and core antigen diagnostic assays.

The company's revenue growth resulted from acquisitions, but Quest faced headwinds from PAMA pricing and reductions in hepatitis C genotyping and vitamin D testing.

Researchers have established that two simple tests can determine whether a person meets guidelines to receive antiviral treatment.

The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.

The companies will initially plan to acquire the required regulatory approvals in India for the Genedrive HCV ID kit.

The firm noted that the premarket approval means that the three major viral load assays that most laboratories run for patients are now available on a single system.

The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.

The assays are for diagnosing hepatitis B infection in individuals with acute or chronic hepatitis B, or who are recovering from hepatitis B infection.

Medcis Pathlabs and its associates and attendees will buy Co-Diagnostics' tests for hepatitis B, hepatitis C, HIV, and human papillomavirus.

Pages